![](/img/cover-not-exists.png)
A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
Fleischmann, Roy M., Damjanov, Nemanja S., Kivitz, Alan J., Legedza, Anna, Hoock, Thomas, Kinnman, NilsVolume:
67
Language:
english
Journal:
Arthritis & Rheumatology
DOI:
10.1002/art.38949
Date:
February, 2015
File:
PDF, 479 KB
english, 2015